Almac Clinical Services LLC   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Audubon PA United States (1996)

Organization Overview

First Clinical Trial
2015
NCT03427073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Almac | Almac Clinical Technologies | Almac Clinical Technologies, LLC | Almac Discovery

Active Ingredients

Drugs in Phase 4 Trials (2)

dexmethylphenidate (focalin) (2 trials)

serdexmethylphenidate (AZSTARYS) (2 trials)

Drugs in Phase 3 Trials (5)

io102 (2 trials)

io103 (1 trial)

macitentan (opsumit) (3 trials)

pembrolizumab (keytruda) (2 trials)

tadalafil (cialis) (1 trial)

Drugs in Phase 2 Trials (1)

vf001-dp (1 trial)

Drugs in Phase 1 Trials (1)

alm201 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 1)

Cardiovascular Diseases (Phase 2)

Familial Primary Pulmonary Hypertension (Phase 3)

Heart Diseases (Phase 3)

Heart Failure (Phase 2)

Hypertension (Phase 3)

Leg Ulcer (Phase 2)

Ovarian Neoplasms (Phase 1)

Pathologic Processes (Phase 2)

Skin Diseases (Phase 2)

Skin Ulcer (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 9